Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | MAOB | P27338 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 2/20 | 0.41 |
| ▸ | WDR5 | P61964 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408306 | 0.86 | ALDH1A1 (0.64) | MAPTMAOAMAOBALDH1A1CA2 | |
| SCHEMBL7557350 | 0.76 | LMNA (0.44) | MAPTMAOAMAOBALDH1A1LMNA | |
| SCHEMBL19605694 | 0.74 | MAPT (0.58) | MAPTMAOAALDH1A1CA2CA5A | |
| SCHEMBL1525245 | 0.74 | ALDH1A1 (0.52) | MAPTALDH1A1CA2CA5ALMNA | |
| SCHEMBL469852 | 0.74 | ALDH1A1 (0.52) | MAPTMAOAMAOBALDH1A1CA2 | |
| SCHEMBL13879111 | 0.74 | TSHR (0.42) | MAPTMAOAMAOBALDH1A1CA2 | |
| SCHEMBL10445656 | 0.74 | ALDH1A1 (0.52) | MAPTALDH1A1CA2CA5APOLB | |
| SCHEMBL171086 | 0.74 | MAPT (0.58) | MAPTALDH1A1CA2CA5ALMNA | |
| SCHEMBL126505 | 0.74 | CA2 (0.54) | MAPTALDH1A1CA2CA5AHTT | |
| SCHEMBL17448755 | 0.74 | ALDH1A1 (0.52) | MAPTALDH1A1CA2CA5APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399942-A1 | FLUORESCENT DYE OIL TRACER COMPOSITIONS | SAUDI ARABIAN OIL COMPANY (SA) | 2023-12-14 | — | — | US | disclosed |
| CN-113292443-B | Process for producing amides | 长沙理工大学 | 2022-07-19 | — | — | CN | disclosed |
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | THE UAB RESEARCH FOUNDATION | 2022-01-27 | — | — | US | disclosed |
| CN-113292443-A | Process for producing amides | 长沙理工大学 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020061412-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| CN-107235875-B | A method of synthesis 1,2,2- trifluoro-ethylene sulfide compound | 福州大学 | 2019-02-22 | — | — | CN | disclosed |
| CN-107235875-A | A kind of method for synthesizing 1,2,2 trifluoro-ethylene sulfide compounds | 福州大学 | 2017-10-10 | — | — | CN | disclosed |
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| US-8883827-B2 | Azole derivatives as WTN pathway inhibitors | OSLO UNIVERSITY HOSPITAL HF (NO) | 2014-11-11 | — | — | US | disclosed |
| US-20010031841-A1 | Procatalysts, catalyst systems, and use in olefin polymerization | WESTLAKE LONGVIEW CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-20010029286-A1 | Procatalysts, catalyst systems, and use in OLEFIN polymerization | EASTMAN CHEMICAL COMPANY, A CORP. OF DELAWARE | 2001-10-11 | — | — | US | disclosed |
| US-20010025005-A1 | Procatalysts, catalyst systems, and use in olefin polymerization | EASTMAN CHEMICAL COMPANY, A CORPORATION OF DELAWARE | 2001-09-27 | — | — | US | disclosed |
| WO-2001051527-A1 | PROCATALYSTS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051526-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051529-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001051528-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2000075202-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075203-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075204-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024877-A1 | COMPOUNDS WITH COPPER- OR ZINC-ACTIVATED TOXICITY AGAINST MICROBIAL INFECTION | SLC39A11, CNBP, SLC39A3 | MAPT 2375/4885MAOA 3069/4885MAOB 3536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.